A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors.
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.

Read More
Topics:
Cannabis,
fsd pharma,
Endocannabinoid System (ECS),
Palmitolylethonalamide (PEA),
ultramicronized-PEA,
fsd,
FSD201,
medical cannabis,
covid19,
coronovirus
An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
immunotherapy,
CEL-SCI,
infectious diseases,
leaps,
cancer,
autoimmune,
head and neck cancer,
squamous cell carcinoma,
rheumatoid arthritis,
covid19,
cervical dysplasia